Serotonin-noradrenalin reuptake inhibitors in the treatment of non-malignant pain syndromes; a systematic review
summary
background Chronic pain and depressive symptoms are often comorbid. Antidepressants seem to influence not only the symptoms of depression but also the perception of pain.
aim To give a systematic overview of the efficacy and safety of serotonin-noradrenalin reuptake inhibitors (snri) in the treatment of chronic non-malignant pain syndromes.
methods We reviewed the literature by means of PubMed and PsycInfo using combinations of the words 'pain' 'venlafaxine' and 'duloxetine'. We selected clinical studies that investigated the influence of snris on pain perception.
results Fourteen articles met our selection criteria. Medical conditions involved were fibromyalgia, diabetic neuropathy and post mastectomy pain. Twelve studies demonstrated the efficacy and safety of venlafaxine and duloxetine in the treatment of non-malignant pain.
conclusion The results revealed that snris are effective in reducing pain particularly in the treatment of diabetic neuropathy. Results with regard to the other medical conditions are less clear. More research is needed to find out in which medical conditions snris have a significant pain reducing effect and why this effect does not hold in the case of other medical conditions.